Figure 5
Figure 5. CML-iPSC derived hematopoietic cells recovered the sensitivity to imatinib. (A) Imatinib but not the vehicle (DMSO) decreased the growth of hematopoietic cells derived from CML-iPSCs in suspension culture. (B) Various concentrations of imatinib were added to the culture of iPSC derived hematopoietic cells for 4 days. CML-iPSC–derived CD34+ hematopoietic cells (CML-HC_1 and CML-HC_2), normal iPSC-derived hematopoietic cells (nor-HC), and K562 cells were used for analyses. Relative cell counts compared with the vehicle control were plotted. Shown is the mean of a single experiment conducted in triplicate as a representative of 3 independent experiments. (C) Imatinib (10μM) was added to the suspension culture of CML-iPSC–derived hematopoietic cells for 4 days. The immature cell fraction (CD34+CD38−CD90+CD45+) showed resistance similar to CML-iPSCs, although more differentiated cells (CD34−CD45+) showed the sensitivity to imatinib. Relative cell counts compared with the vehicle control was plotted.

CML-iPSC derived hematopoietic cells recovered the sensitivity to imatinib. (A) Imatinib but not the vehicle (DMSO) decreased the growth of hematopoietic cells derived from CML-iPSCs in suspension culture. (B) Various concentrations of imatinib were added to the culture of iPSC derived hematopoietic cells for 4 days. CML-iPSC–derived CD34+ hematopoietic cells (CML-HC_1 and CML-HC_2), normal iPSC-derived hematopoietic cells (nor-HC), and K562 cells were used for analyses. Relative cell counts compared with the vehicle control were plotted. Shown is the mean of a single experiment conducted in triplicate as a representative of 3 independent experiments. (C) Imatinib (10μM) was added to the suspension culture of CML-iPSC–derived hematopoietic cells for 4 days. The immature cell fraction (CD34+CD38CD90+CD45+) showed resistance similar to CML-iPSCs, although more differentiated cells (CD34CD45+) showed the sensitivity to imatinib. Relative cell counts compared with the vehicle control was plotted.

Close Modal

or Create an Account

Close Modal
Close Modal